Press Releases

MGEN $0.50 $ - 0.06 (11.25%)

Press Releases

Search Press Releases
  
Subscribe for Email Alerts
3/11/2020
4:05 PM ET
Earnings Release

miRagen Reports Fourth Quarter and Full Year 2019 Financial Results

3/11/2020

Completed enrollment of 37 patients in the Phase 2 SOLAR trial of cobomarsen in CTCL; expects to report topline data in Q3 2020Completed initial planned enrollment of the Phase 1 trial of cobomarsen i...

 Continue Reading
2/20/2020
8:00 AM ET
Press Release

miRagen Therapeutics to Report Fourth Quarter and Full Year 2019 Financial Results on March 11, 2020

2/20/2020

BOULDER, Colo., Feb. 20, 2020 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted thera...

 Continue Reading
2/7/2020
9:00 AM ET
Press Release

miRagen Announces Pricing of $15.0 Million Public Offering of Common Stock and Warrants to Purchase Common Stock

2/7/2020

BOULDER, Colo., Feb. 07, 2020 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted thera...

 Continue Reading
2/6/2020
4:03 PM ET
Press Release

miRagen Announces Proposed Public Offering of Common Stock and Warrants to Purchase Common Stock

2/6/2020

BOULDER, Colo., Feb. 06, 2020 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted thera...

 Continue Reading
1/30/2020
7:00 AM ET
Press Release

miRagen Therapeutics Announces Positive Data for Cobomarsen in Adult T-Cell Leukemia/lymphoma Patients With Residual Disease

1/30/2020

Cobomarsen-treated adult T-cell leukemia/lymphoma (ATLL) patients with residual disease had a median survival time (MST) of 26 months compared with 7.4 months in a historical cohort- - -

Me...

 Continue Reading
Displaying 1 to 5 (of 94 releases)